Literature DB >> 2999236

Cachectin/tumor necrosis factor: production, distribution, and metabolic fate in vivo.

B A Beutler, I W Milsark, A Cerami.   

Abstract

A highly specific radioreceptor assay for cachectin/tumor necrosis factor (TNF) was utilized to measure the time course of lipopolysaccharide (LPS)-induced hormone production in rabbits. Cachectin/TNF bioactivity was monitored in the same serum samples by measuring lipoprotein lipase (LPL) suppression in 3T3-L1 cells. Cachectin/TNF is produced in large quantities by LPS-treated rabbits without priming by bacillus Calmette Guérin, C. parvum, or other agents. Nanomolar concentrations of the hormone are achieved, with peak levels occurring at 2 hr postinjection; the hormone is rapidly cleared thereafter. In separate studies, mice were used to assess the distribution and metabolic fate of cachectin/TNF. Radioiodinated hormone is cleared from the plasma with a half-life of 6 to 7 min. Studies of the tissue distribution of label after injection demonstrate that liver, kidneys, skin, and gastrointestinal tract take up most of the hormone. Electrophoretic analysis of tissues recovered from injected animals suggests that the hormone is very rapidly degraded after binding.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2999236

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  166 in total

1.  Induction and potential biological relevance of a Ca(2+)-independent nitric oxide synthase in the myocardium.

Authors:  R Schulz; E Nava; S Moncada
Journal:  Br J Pharmacol       Date:  1992-03       Impact factor: 8.739

2.  Population robustness arising from cellular heterogeneity.

Authors:  Pawel Paszek; Sheila Ryan; Louise Ashall; Kate Sillitoe; Claire V Harper; David G Spiller; David A Rand; Michael R H White
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-07       Impact factor: 11.205

3.  Recombinant human tumour necrosis factor (rTNF)2 enhances leukotriene biosynthesis in neutrophils and eosinophils stimulated with the Ca2+ ionophore A23187.

Authors:  R Roubin; P P Elsas; W Fiers; A J Dessein
Journal:  Clin Exp Immunol       Date:  1987-11       Impact factor: 4.330

4.  Soluble tumor necrosis factor receptors and heart failure risk in older adults: Health, Aging, and Body Composition (Health ABC) Study.

Authors:  Catherine N Marti; Hassan Khan; Douglas L Mann; Vasiliki V Georgiopoulou; Kirsten Bibbins-Domingo; Tamara Harris; Annemarie Koster; Anne Newman; Stephen B Kritchevsky; Andreas P Kalogeropoulos; Javed Butler
Journal:  Circ Heart Fail       Date:  2013-12-09       Impact factor: 8.790

5.  Synergic action between tumor necrosis factor and endotoxins or poly(A.U) on cultured bovine endothelial cells.

Authors:  P A van de Wiel; R H Pieters; A van der Pijl; N Bloksma
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

6.  Effect of recombinant tumour necrosis factor on acute infection in mice with Toxoplasma gondii or Trypanosoma cruzi.

Authors:  C M Black; D M Israelski; Y Suzuki; J S Remington
Journal:  Immunology       Date:  1989-12       Impact factor: 7.397

7.  Mediation by nitric oxide formation in the preoptic area of endotoxin and tumour necrosis factor-induced inhibition of water intake in the rat.

Authors:  G Calapai; G Mazzaglia; M Cilia; B Zingarelli; F Squadrito; A P Caputi
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

8.  A Minimal Physiologically Based Pharmacokinetic Model with a Nested Endosome Compartment for Novel Engineered Antibodies.

Authors:  Dongfen Yuan; Frederik Rode; Yanguang Cao
Journal:  AAPS J       Date:  2018-03-14       Impact factor: 4.009

9.  Tumor necrosis factor-alpha eliminates binding of NF-Y and an octamer-binding protein to the lipoprotein lipase promoter in 3T3-L1 adipocytes.

Authors:  C L Morin; I R Schlaepfer; R H Eckel
Journal:  J Clin Invest       Date:  1995-04       Impact factor: 14.808

10.  Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD.

Authors:  Elizabeth Sapey; Ali Ahmad; Darren Bayley; Paul Newbold; Noel Snell; Paul Rugman; Robert A Stockley
Journal:  J Clin Immunol       Date:  2009-03-17       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.